Structure-Based Drug Discovery is a collection of methods which exploit the ability to determine and analyse the three-dimensional structure of biological molecules. These methods have been adopted and enhanced to improve the speed and quality of drug discovery. After an introductory overview of the principles and applications of structure-based methods in drug discovery, the essential features of the various methods are explored. Chapters on X-ray crystallography, NMR spectroscopy, computational chemistry and molecular modelling describe how these particular techniques have been enhanced to…mehr
Structure-Based Drug Discovery is a collection of methods which exploit the ability to determine and analyse the three-dimensional structure of biological molecules. These methods have been adopted and enhanced to improve the speed and quality of drug discovery. After an introductory overview of the principles and applications of structure-based methods in drug discovery, the essential features of the various methods are explored. Chapters on X-ray crystallography, NMR spectroscopy, computational chemistry and molecular modelling describe how these particular techniques have been enhanced to support rational drug discovery, with discussions on developments such as high-throughput structure determination, probing protein-ligand interactions by NMR spectroscopy, virtual screening, and fragment-based drug discovery. The concluding chapters complement the overview of methods by presenting case histories which demonstrate the major impact that structure-based methods have had on the drug discovery process. Written by international experts from industry and academia, this comprehensive introduction to the methods and practice of structure-based drug discovery not only illustrates leading-edge science but also provides useful scientific background for the non-expert reader. The book presents a balanced appraisal of what structure-based methods can and cannot contribute to drug discovery. It will appeal to industrial and academic researchers in pharmaceutical sciences, medicinal chemistry and chemical biology, as well as providing an insight into the field for recent graduates in the biomolecular sciences. TOC:3D Structure and the Drug Discovery Process.- Structure Determination: Crystallography for Structure-based Drug Design.- Molecular Modelling.- Applications of NMR in Structure-based Drug Design.- Fragment Screening: An Introduction.- Iterative Structure-based Screening of Virtual Chemical Libraries and Factor Xa: Finding the Orally-Available Antithrombotic Candidate LY517717.- Anti-Influenza Drugs from Sialidase Inhibitors.- Isoform Specificity: The Design of Estrogen Receptor-Selective Compounds.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Rod Hubbard has been developing and applying methods to study aspects of protein structure for the past twenty five years. In the 1980s, he developed the molecular modelling and graphics programs QUANTA which is still in use today. From the mid 1980s he helped to build up the Structural Biology Laboratory at York of which he was Director from 1992-2001. During the 1990s, his personal research interests focused on protein-ligand interactions and the structures of therapeutically important proteins such as humanized antibodies, kinases, proteases and nuclear receptors. Since 2001, he has spent part of his time at Vernalis (formerly RiboTargets), establishing structure-based drug discovery. As well as the positions at York and Vernalis, he is also a consultant on structure-based discovery methods to various software, biotechnology and pharmaceutical companies.
Inhaltsangabe
Chapter 1: 3D Structure and the Drug Discovery Process 1: Introduction 2: The Drug Discovery Process 3: What is Structure-based Drug Discovery? 4: The Evolution of the Ideas of Structure-based Drug Discovery 5: What isn't in this Book 6: Concluding Remarks References Chapter 2: Structure Detemination - Crystallography for Structure-based Drug Design 1: What is X-ray Crystallography? 2: What is required to Produce a Crystal Structure? 3: Crystallisability of Proteins 4: How Does the X-ray Data Relate to the Electron Density? The Phase Problem 5: Electron Density Map Interpretation and Atomic Model of the Protein 6: Useful Crystallographic Therminology when Utilising Crystal Structures 7: The Structure Determination Process 8: Recent technological Advances 9: The Role of Crystal Structures in the Discovery Process 10: The Optimal SBDD System 11: The Impact of Structural Genomics 12: Producing a Biologically Relevant Structure 13: Phosphorylation 14: Balancing Solubility with Crystallisability 15: Engineering Solubility 16: Specific Crystal Packing Engineering 17: Engineering Stability 18: Use of Surrogate Proteins References Chapter 3: Molecular Modelling 1: Introduction 2: Methods 3: Applications 4: Conclusion References Chapter 4: Applications of NMR in Structure-based Drug Design 1: Introduction 2: Studying Ligand/Receptor Interactions by NMR 3: NMR in Structure-based Lead Optimization 4: Other Applications of NMR in SBDD 5: Conclusion and Outlook References Chapter 5: Fragment Screening - An Introduction 1: Introduction 2: The Concept of Drug Likeness 3: The Evolution of Lead-likeness and Fragment Screening 4: Finding Fragments by Screening 5: The Design of Fragment Screening Sets 6: Turning Fragment Hits into Leads 7:Summary References Chapter 6: Iterative Structure-based Screening of Virtual Chemical Libraries and Factor Xa: Finding the Orally Available Antithrombotic Candadate LY517717 1: Introduction 2: Morphology of the Factor Xa Active Site 3: Structure-based Library Design 4: Design Strategy for Factor Xa 5: Introducing Oral Availability 6: Non-basic S1 Series 7: Oral Antithrombotic Activity 8: Conclusion References Chapter 7: Anti-influenza Drugs from Sialidase Inhibitors 1: Introduction 2: Influenza Viruses 3: Early Attempts to Discover Neuraminidase Inhibitors 4: Neuraminidase Structure 5: Structure-based Discovery of Inhibitors 6: Retrospective Analyses of Inhibitor-binding 7: Laboratory Studies of Inhibitor Resistant Variants 8: Clinical Studies of Drug Resistance 9: Drug Profiles Conclusions References Chapter 8: Isoform Specificity: The Design of Estrogen Receptor- Selective Compounds 1: Introduction 2: Structure-based Design Methodology 3: The Design of Aryl Diphenolic Azoles as ER? Selective Agonists 4: Learning From and Moving Beyond the Genistein Scaffold 5: Evaluation of ER? Selective Compounds in Biological Assays Conclusions Acknowledgements References
Chapter 1: 3D Structure and the Drug Discovery Process 1: Introduction 2: The Drug Discovery Process 3: What is Structure-based Drug Discovery? 4: The Evolution of the Ideas of Structure-based Drug Discovery 5: What isn't in this Book 6: Concluding Remarks References Chapter 2: Structure Detemination - Crystallography for Structure-based Drug Design 1: What is X-ray Crystallography? 2: What is required to Produce a Crystal Structure? 3: Crystallisability of Proteins 4: How Does the X-ray Data Relate to the Electron Density? The Phase Problem 5: Electron Density Map Interpretation and Atomic Model of the Protein 6: Useful Crystallographic Therminology when Utilising Crystal Structures 7: The Structure Determination Process 8: Recent technological Advances 9: The Role of Crystal Structures in the Discovery Process 10: The Optimal SBDD System 11: The Impact of Structural Genomics 12: Producing a Biologically Relevant Structure 13: Phosphorylation 14: Balancing Solubility with Crystallisability 15: Engineering Solubility 16: Specific Crystal Packing Engineering 17: Engineering Stability 18: Use of Surrogate Proteins References Chapter 3: Molecular Modelling 1: Introduction 2: Methods 3: Applications 4: Conclusion References Chapter 4: Applications of NMR in Structure-based Drug Design 1: Introduction 2: Studying Ligand/Receptor Interactions by NMR 3: NMR in Structure-based Lead Optimization 4: Other Applications of NMR in SBDD 5: Conclusion and Outlook References Chapter 5: Fragment Screening - An Introduction 1: Introduction 2: The Concept of Drug Likeness 3: The Evolution of Lead-likeness and Fragment Screening 4: Finding Fragments by Screening 5: The Design of Fragment Screening Sets 6: Turning Fragment Hits into Leads 7:Summary References Chapter 6: Iterative Structure-based Screening of Virtual Chemical Libraries and Factor Xa: Finding the Orally Available Antithrombotic Candadate LY517717 1: Introduction 2: Morphology of the Factor Xa Active Site 3: Structure-based Library Design 4: Design Strategy for Factor Xa 5: Introducing Oral Availability 6: Non-basic S1 Series 7: Oral Antithrombotic Activity 8: Conclusion References Chapter 7: Anti-influenza Drugs from Sialidase Inhibitors 1: Introduction 2: Influenza Viruses 3: Early Attempts to Discover Neuraminidase Inhibitors 4: Neuraminidase Structure 5: Structure-based Discovery of Inhibitors 6: Retrospective Analyses of Inhibitor-binding 7: Laboratory Studies of Inhibitor Resistant Variants 8: Clinical Studies of Drug Resistance 9: Drug Profiles Conclusions References Chapter 8: Isoform Specificity: The Design of Estrogen Receptor- Selective Compounds 1: Introduction 2: Structure-based Design Methodology 3: The Design of Aryl Diphenolic Azoles as ER? Selective Agonists 4: Learning From and Moving Beyond the Genistein Scaffold 5: Evaluation of ER? Selective Compounds in Biological Assays Conclusions Acknowledgements References
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
